Y-MABS THERAPEUTICS, INC.

(YMAB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Y-mAbs Therapeutics, Inc. Announces Appointment of Sue Smith as Chief Commercial Officer, Effective January 1, 2022

12/17/2021 | 06:03am EDT

Y-mAbs Therapeutics, Inc. announced the appointment of Sue Smith as the Company's Senior Vice President and Chief Commercial Officer effective as of January 1, 2022. Ms. Smith has more than 25 years of U.S and global oncology and rare disease experience and for the past almost 10 years she was employed by Kyowa Kirin, Inc., most recently as Vice President, U.S Oncology Business Unit Head.


© S&P Capital IQ 2021
All news about Y-MABS THERAPEUTICS, INC.
05/19Y-mAbs Therapeutics Appoints President Thomas Gad Interim CEO
MT
05/19Y-MABS THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/10Wedbush Adjusts Price Target for Y-mAbs Therapeutics to $21 From $28, Maintains Outperf..
MT
05/10TRANSCRIPT : Y-mAbs Therapeutics, Inc., Q1 2022 Earnings Call, May 10, 2022
CI
05/09Y-MABS THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/09Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments
AQ
05/09Y-mAbs Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/03Y-mAbs to Announce First Quarter 2022 Financial and Operating Results on May 9, 2022
AQ
04/28Wedbush Cuts Y-mAbs Therapeutics' Price Target to $28 From $36, Adjusting Nivatrotamab,..
MT
04/27Y MABS THERAPEUTICS : mAbs Announces Executive Management Changes and Provides 2022 Revenu..
PU
More news
Analyst Recommendations on Y-MABS THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 63,4 M - -
Net income 2022 -89,4 M - -
Net cash 2022 197 M - -
P/E ratio 2022 -4,96x
Yield 2022 -
Capitalization 438 M 438 M -
EV / Sales 2022 3,80x
EV / Sales 2023 2,88x
Nbr of Employees 148
Free-Float 87,7%
Chart Y-MABS THERAPEUTICS, INC.
Duration : Period :
Y-mAbs Therapeutics, Inc. Technical Analysis Chart | YMAB | US9842411095 | MarketScreener
Technical analysis trends Y-MABS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 10,02 $
Average target price 27,83 $
Spread / Average Target 178%
EPS Revisions
Managers and Directors
Thomas Gad President & Chief Executive Officer
Bo Kruse CFO, Secretary. Treasurer & Executive VP
James Irvin Healy Chairman
Torben Lund-Hansen Chief Technology Officer & Senior Vice President
Steen Lisby Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
Y-MABS THERAPEUTICS, INC.-38.19%438
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612